Back
Rate this talk
Your peers have not rated this talk yet.
3-minute watch | Talk 11 of 15

ASCO, EHA & ICML: Expert perspective

Emerging practice-changing data in haematological malignancies

Prof. Max Topp
PERSPECTIVE
ASCO EHA ICML

Prof. Max Topp
University Hospital Würzburg, Würzburg, Germany

Prof. Max Topp, from University of Würzburg, Germany, gives his perspective on emerging data on immunotherapy in R/R DLBCL and multiple myeloma presented during the 2023 summer congress season

Read more

Talks in this series

Prof. Christopher Fox presents an expert perspective
4-minute watch | Talk 1 of 15
ASCO, EHA & ICML: Expert perspective
Updates on front‑line management in NHL
Prof. Christopher Fox presents an expert perspective
4-minute watch
ASCO, EHA & ICML: Expert perspective

Updates on front‑line management in NHL

Prof. Marie José Kersten presents an expert perspective
3-minute watch | Talk 2 of 15
ZUMA-7: Survival outcomes with axicabtagene ciloleucel in 2L DLBCL
Prof. Marie José Kersten
Prof. Marie José Kersten presents an expert perspective
3-minute watch

ZUMA-7: Survival outcomes with axicabtagene ciloleucel in 2L DLBCL

Prof. Marie José Kersten

Dr Miguel-Angel Perales presents an expert perspective
3-minute watch | Talk 3 of 15
ZUMA-7: What is the Q-TWiST analysis?
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents an expert perspective
3-minute watch

ZUMA-7: What is the Q-TWiST analysis?

Dr Miguel-Angel Perales

Dr Miguel-Angel Perales presents an expert perspective
2-minute watch | Talk 4 of 15
ZUMA-7: My key takeaways
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents an expert perspective
2-minute watch

ZUMA-7: My key takeaways

Dr Miguel-Angel Perales

Dr Wendy Osborne presents an expert perspective
2-minute watch | Talk 5 of 15
Is there a role for consolidation radiotherapy in primary mediastinal large B‑cell lymphoma?
Dr Wendy Osborne
Dr Wendy Osborne presents an expert perspective
2-minute watch

Is there a role for consolidation radiotherapy in primary mediastinal large B‑cell lymphoma?

Dr Wendy Osborne

Dr Matthew Lunning presents an expert perspective
4-minute watch | Talk 7 of 15
Highlights of summer congresses
Dr Matthew Lunning
Dr Matthew Lunning presents an expert perspective
4-minute watch

Highlights of summer congresses

Dr Matthew Lunning

Dr Michael Dickinson presents an expert perspective
3-minute watch | Talk 8 of 15
Latest data from CAR T‑cell therapy and bispecific antibody use in DLBCL
Dr Michael Dickinson
Dr Michael Dickinson presents an expert perspective
3-minute watch

Latest data from CAR T‑cell therapy and bispecific antibody use in DLBCL

Dr Michael Dickinson

Dr Kate Cwynarski presents an expert perspective
3-minute watch | Talk 9 of 15
CAR T‑cell therapy in the management of primary CNS lymphoma
Dr Kate Cwynarski
Dr Kate Cwynarski presents an expert perspective
3-minute watch

CAR T‑cell therapy in the management of primary CNS lymphoma

Dr Kate Cwynarski

Dr Gloria Iacobani presents an expert perspective
2-minute watch | Talk 10 of 15
The effect of bendamustine bridging on CAR T outcomes
Dr Gloria Iacoboni
Dr Gloria Iacobani presents an expert perspective
2-minute watch

The effect of bendamustine bridging on CAR T outcomes

Dr Gloria Iacoboni

Prof. Max Topp presents an expert perspective
3-minute watch | Talk 11 of 15
Emerging practice-changing data in haematological malignancies
Prof. Max Topp
Prof. Max Topp presents an expert perspective
3-minute watch

Emerging practice-changing data in haematological malignancies

Prof. Max Topp

Dr Robin Sanderson presents an expert perspective
3-minute watch | Talk 12 of 15
Real-world data supporting CAR T‑cell therapy in non‑Hodgkin's lymphoma
Dr Robin Sanderson
Dr Robin Sanderson presents an expert perspective
3-minute watch

Real-world data supporting CAR T‑cell therapy in non‑Hodgkin's lymphoma

Dr Robin Sanderson

Dr Keith Wilson presents an expert perspective
8-minute watch | Talk 13 of 15
What is the role of patient prehabilitation prior to CAR T‑cell therapy?
Dr Keith Wilson
Dr Keith Wilson presents an expert perspective
8-minute watch

What is the role of patient prehabilitation prior to CAR T‑cell therapy?

Dr Keith Wilson

Lorna Warwick presents an expert perspective
5-minute watch | Talk 14 of 15
Supporting patients and caregivers through their CAR T‑cell therapy journey
Ms Lorna Warwick
Lorna Warwick presents an expert perspective
5-minute watch

Supporting patients and caregivers through their CAR T‑cell therapy journey

Ms Lorna Warwick

Dr Bijal Shah presents an expert perspective
10-minute watch | Talk 15 of 15
Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data
Dr Bijal Shah
Dr Bijal Shah presents an expert perspective
10-minute watch

Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data

Dr Bijal Shah

Prof. Christopher Fox presents an expert perspective
4-minute watch | Talk 1 of 15
ASCO, EHA & ICML: Expert perspective
Updates on front‑line management in NHL
Prof. Christopher Fox presents an expert perspective
4-minute watch
ASCO, EHA & ICML: Expert perspective

Updates on front‑line management in NHL

Prof. Marie José Kersten presents an expert perspective
3-minute watch | Talk 2 of 15
ZUMA-7: Survival outcomes with axicabtagene ciloleucel in 2L DLBCL
Prof. Marie José Kersten
Prof. Marie José Kersten presents an expert perspective
3-minute watch

ZUMA-7: Survival outcomes with axicabtagene ciloleucel in 2L DLBCL

Prof. Marie José Kersten

Dr Miguel-Angel Perales presents an expert perspective
3-minute watch | Talk 3 of 15
ZUMA-7: What is the Q-TWiST analysis?
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents an expert perspective
3-minute watch

ZUMA-7: What is the Q-TWiST analysis?

Dr Miguel-Angel Perales

Dr Miguel-Angel Perales presents an expert perspective
2-minute watch | Talk 4 of 15
ZUMA-7: My key takeaways
Dr Miguel-Angel Perales
Dr Miguel-Angel Perales presents an expert perspective
2-minute watch

ZUMA-7: My key takeaways

Dr Miguel-Angel Perales

Dr Wendy Osborne presents an expert perspective
2-minute watch | Talk 5 of 15
Is there a role for consolidation radiotherapy in primary mediastinal large B‑cell lymphoma?
Dr Wendy Osborne
Dr Wendy Osborne presents an expert perspective
2-minute watch

Is there a role for consolidation radiotherapy in primary mediastinal large B‑cell lymphoma?

Dr Wendy Osborne

Dr Matthew Lunning presents an expert perspective
4-minute watch | Talk 7 of 15
Highlights of summer congresses
Dr Matthew Lunning
Dr Matthew Lunning presents an expert perspective
4-minute watch

Highlights of summer congresses

Dr Matthew Lunning

Dr Michael Dickinson presents an expert perspective
3-minute watch | Talk 8 of 15
Latest data from CAR T‑cell therapy and bispecific antibody use in DLBCL
Dr Michael Dickinson
Dr Michael Dickinson presents an expert perspective
3-minute watch

Latest data from CAR T‑cell therapy and bispecific antibody use in DLBCL

Dr Michael Dickinson

Dr Kate Cwynarski presents an expert perspective
3-minute watch | Talk 9 of 15
CAR T‑cell therapy in the management of primary CNS lymphoma
Dr Kate Cwynarski
Dr Kate Cwynarski presents an expert perspective
3-minute watch

CAR T‑cell therapy in the management of primary CNS lymphoma

Dr Kate Cwynarski

Dr Gloria Iacobani presents an expert perspective
2-minute watch | Talk 10 of 15
The effect of bendamustine bridging on CAR T outcomes
Dr Gloria Iacoboni
Dr Gloria Iacobani presents an expert perspective
2-minute watch

The effect of bendamustine bridging on CAR T outcomes

Dr Gloria Iacoboni

Prof. Max Topp presents an expert perspective
3-minute watch | Talk 11 of 15
Emerging practice-changing data in haematological malignancies
Prof. Max Topp
Prof. Max Topp presents an expert perspective
3-minute watch

Emerging practice-changing data in haematological malignancies

Prof. Max Topp

Dr Robin Sanderson presents an expert perspective
3-minute watch | Talk 12 of 15
Real-world data supporting CAR T‑cell therapy in non‑Hodgkin's lymphoma
Dr Robin Sanderson
Dr Robin Sanderson presents an expert perspective
3-minute watch

Real-world data supporting CAR T‑cell therapy in non‑Hodgkin's lymphoma

Dr Robin Sanderson

Dr Keith Wilson presents an expert perspective
8-minute watch | Talk 13 of 15
What is the role of patient prehabilitation prior to CAR T‑cell therapy?
Dr Keith Wilson
Dr Keith Wilson presents an expert perspective
8-minute watch

What is the role of patient prehabilitation prior to CAR T‑cell therapy?

Dr Keith Wilson

Lorna Warwick presents an expert perspective
5-minute watch | Talk 14 of 15
Supporting patients and caregivers through their CAR T‑cell therapy journey
Ms Lorna Warwick
Lorna Warwick presents an expert perspective
5-minute watch

Supporting patients and caregivers through their CAR T‑cell therapy journey

Ms Lorna Warwick

Dr Bijal Shah presents an expert perspective
10-minute watch | Talk 15 of 15
Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data
Dr Bijal Shah
Dr Bijal Shah presents an expert perspective
10-minute watch

Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data

Dr Bijal Shah

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.